Frontiers in Oncology | Thoracic Oncology

Original Research

Published on 03 May 2022

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

in Thoracic Oncology

Jiachun Sun
Zhiyi Jiang
Tanyou Shan
Ruina Yang
Dejiu Kong
Junshuai Rui
Xinyang Li
Guoqiang Kong
Baoping Chang

Frontiers in Oncology

doi 10.3389/fonc.2022.833486

5,801 views
15 citations

Original Research

Published on 03 May 2022

Deciphering the Role of Shugoshin-Like Protein 1 in Lung Adenocarcinoma: A Comprehensive Analysis and In Vitro Study

in Thoracic Oncology

Yixiao Yuan
Juan Wang
Dahang Zhang
Lin Tang
Lincan Duan
Xiulin Jiang

Frontiers in Oncology

doi 10.3389/fonc.2022.898920

2,719 views
5 citations

Original Research

Published on 03 May 2022

Gut Microbiome Was Highly Related to the Regulation of Metabolism in Lung Adenocarcinoma Patients

in Thoracic Oncology

Sheng Wang
Huachun Chen
Huizhen Yang
Kejin Zhou
Fan Bai
Xiaoyu Wu
Hanwen Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.790467

4,927 views
11 citations

Review

Published on 02 May 2022

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma

in Thoracic Oncology

Agnes Y. Choi
Anand Singh
Danyi Wang
Karthik Pittala
Chuong D. Hoang

Frontiers in Oncology

doi 10.3389/fonc.2022.886430

3,837 views
5 citations

Systematic Review

Published on 29 Apr 2022

Differential Diagnostic Value of Histology in MPLC and IPM: A Systematic Review and Meta-Analysis

in Thoracic Oncology

Sen Tian
Fuqi Li
Jin Pu
Yi Zheng
Hui Shi
Yuchao Dong
Ruohua Chen
Chong Bai

Frontiers in Oncology

doi 10.3389/fonc.2022.871827

10,853 views
13 citations

Original Research

Published on 29 Apr 2022

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

in Thoracic Oncology

Wengang Zhang
Xiaoling Shang
Fei Yang
Wenfei Han
Handai Xia
Ni Liu
Yanguo Liu
Xiuwen Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.867788

4,346 views
15 citations

Brief Research Report

Published on 28 Apr 2022

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma

in Thoracic Oncology

Francinne T. Tostes
Miguel Zugman
Vitor R. Paes
Gustavo Schvartsman

Frontiers in Oncology

doi 10.3389/fonc.2022.836751

2,845 views
5 citations

Original Research

Published on 28 Apr 2022

A Multi-Classification Model for Predicting the Invasiveness of Lung Adenocarcinoma Presenting as Pure Ground-Glass Nodules

in Thoracic Oncology

Fan Song
Lan Song
Tongtong Xing
Youdan Feng
Xiao Song
Peng Zhang
Tianyi Zhang
Zhenchen Zhu
Wei Song
Guanglei Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.800811

3,745 views
11 citations

Original Research

Published on 28 Apr 2022

The Difference and Significance of Parietal Pleura Invasion and Rib Invasion in Pathological T Classification With Non-Small Cell Lung Cancer

in Thoracic Oncology

Lei-Lei Wu
Chong-Wu Li
Kun Li
Li-Hong Qiu
Shu-Quan Xu
Wei-Kang Lin
Guo-Wei Ma
Zhi-Xin Li
Dong Xie

Frontiers in Oncology

doi 10.3389/fonc.2022.878482

3,477 views
12 citations

Brief Research Report

Published on 28 Apr 2022

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

in Thoracic Oncology

James Chih-Hsin Yang
Martin Schuler
Sanjay Popat
Satoru Miura
Keunchil Park
Antonio Passaro
Filippo De Marinis
Flavio Solca
Angela Märten
Edward S. Kim

Frontiers in Oncology

doi 10.3389/fonc.2022.834704

14,689 views
53 citations

Original Research

Published on 28 Apr 2022

CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma

in Thoracic Oncology

Ningning Zhu
Yueyang Yang
Haitong Wang
Peng Tang
Hongdian Zhang
Haiyan Sun
Lei Gong
Zhentao Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.822849

7,055 views
16 citations

Original Research

Published on 27 Apr 2022

MR-Guided Microwave Ablation for Lung Malignant Tumor: A Single Center Prospective Study

in Thoracic Oncology

Ruixiang Lin
Yan Fang
Jin Chen
QingFeng Lin
Jian Chen
Yuan Yan
Jie Chen
Zhengyu Lin

Frontiers in Oncology

doi 10.3389/fonc.2022.856340

3,359 views
7 citations

Original Research

Published on 26 Apr 2022

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study

in Thoracic Oncology

Xiaoxing Gao
Minjiang Chen
Xiaoyan Liu
Yuequan Shi
Hongge Liang
Qing Zhou
Jing Zhao
Ruili Pan
Wei Zhong
Yan Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.879554

2,685 views
2 citations

Original Research

Published on 22 Apr 2022

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

in Thoracic Oncology

Shen Lin
Yiyuan Li
Dian Gu
Shaohong Luo
Xiaoting Huang
Liangliang Dong
Xiongwei Xu
Peili Lin
Xiuhua Weng

Frontiers in Oncology

doi 10.3389/fonc.2022.857452

4,035 views
2 citations

Case Report

Published on 21 Apr 2022

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

in Thoracic Oncology

Yubo Wang
Rui Han
Mengxiao Zhu
Tingting He
Yong He

Frontiers in Oncology

doi 10.3389/fonc.2022.875313

3,986 views
9 citations

Review

Published on 20 Apr 2022

A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer

in Thoracic Oncology

Maoqing Jiang
Xiaohui Zhang
Yan Chen
Ping Chen
Xiuyu Guo
Lijuan Ma
Qiaoling Gao
Weiqi Mei
Jingfeng Zhang
Jianjun Zheng

Frontiers in Oncology

doi 10.3389/fonc.2022.780186

4,118 views
11 citations

Review

Published on 20 Apr 2022

The Landscape of Immunotherapy Resistance in NSCLC

in Thoracic Oncology

Daniele Frisone
Alex Friedlaender
Alfredo Addeo
Petros Tsantoulis

Frontiers in Oncology

doi 10.3389/fonc.2022.817548

20,049 views
55 citations

Original Research

Published on 14 Apr 2022

Prognostic Implication of Energy Metabolism-Related Gene Signatures in Lung Adenocarcinoma

in Thoracic Oncology

Teng Mu
Haoran Li
Xiangnan Li

Frontiers in Oncology

doi 10.3389/fonc.2022.867470

7,296 views
10 citations

Review

Published on 14 Apr 2022

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs

in Thoracic Oncology

Lorenzo Belluomini
Lorenzo Calvetti
Alessandro Inno
Giulia Pasello
Elisa Roca
Emanuela Vattemi
Antonello Veccia
Jessica Menis
Sara Pilotto

Frontiers in Oncology

doi 10.3389/fonc.2022.840783

12,048 views
29 citations

Review

Published on 12 Apr 2022

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases

in Thoracic Oncology

Thomas Pierret
Niccolò Giaj-Levra
Anne-Claire Toffart
Filippo Alongi
Denis Moro-Sibilot
Elisa Gobbini

Frontiers in Oncology

doi 10.3389/fonc.2022.787080

7,870 views
9 citations

Original Research

Published on 12 Apr 2022

Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract

in Thoracic Oncology

Kai Qian
Yi Deng
William S. Krimsky
Yong-Geng Feng
Jun Peng
Yong-Hang Tai
Hao Peng
Li-Hong Jiang

Frontiers in Oncology

doi 10.3389/fonc.2022.811279

3,926 views
7 citations

Review

Published on 08 Apr 2022

Thymic Carcinoma: A Review

in Thoracic Oncology

Doaa Alqaidy
Cesar A. Moran

Frontiers in Oncology

doi 10.3389/fonc.2022.808019

17,302 views
9 citations

Review

Published on 07 Apr 2022

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

in Thoracic Oncology

Emna Mahfoudhi
Charles Ricordel
Gwendoline Lecuyer
Cécile Mouric
Hervé Lena
Rémy Pedeux

Frontiers in Oncology

doi 10.3389/fonc.2022.853501

11,556 views
7 citations

Review

Published on 06 Apr 2022

Targeting ALK Rearrangements in NSCLC: Current State of the Art

in Thoracic Oncology

Ling Peng
Liping Zhu
Yilan Sun
Justin Stebbing
Giovanni Selvaggi
Yongchang Zhang
Zhentao Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.863461

25,470 views
71 citations

1,969 articles

articles

Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma

Deciphering the Role of Shugoshin-Like Protein 1 in Lung Adenocarcinoma: A Comprehensive Analysis and In Vitro Study

Gut Microbiome Was Highly Related to the Regulation of Metabolism in Lung Adenocarcinoma Patients

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma

Differential Diagnostic Value of Histology in MPLC and IPM: A Systematic Review and Meta-Analysis

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma

A Multi-Classification Model for Predicting the Invasiveness of Lung Adenocarcinoma Presenting as Pure Ground-Glass Nodules

The Difference and Significance of Parietal Pleura Invasion and Rib Invasion in Pathological T Classification With Non-Small Cell Lung Cancer

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma

MR-Guided Microwave Ablation for Lung Malignant Tumor: A Single Center Prospective Study

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer

The Landscape of Immunotherapy Resistance in NSCLC

Prognostic Implication of Energy Metabolism-Related Gene Signatures in Lung Adenocarcinoma

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases

Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract

Thymic Carcinoma: A Review

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

Targeting ALK Rearrangements in NSCLC: Current State of the Art